{"id":46997,"date":"2026-07-29T04:50:00","date_gmt":"2026-07-29T02:50:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=ac5a64f943f09d09ea141327334caa67"},"modified":"2026-07-29T04:50:00","modified_gmt":"2026-07-29T02:50:00","slug":"nasdaq-celc-investigation-alert-kessler-topaz-meltzer-check-llp-encourages-celcuity-inc-nasdaq-celc-investors-to-contact-the-firm","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=46997","title":{"rendered":"NASDAQ: CELC Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm"},"content":{"rendered":"

RADNOR, Pa.--(BUSINESS WIRE)--#classaction<\/a>--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com<\/a>), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Celcuity Inc. (NASDAQ: CELC<\/a>) on behalf of investors who purchased or acquired Celcuity Inc. securities and experienced significant financial losses.<\/p><\/a><\/a>

\nCelcuity Announces Unexpected Delayed Drug Launch<\/span><\/b><\/p>

\nOn July 14, 2026, Celcuity Inc. issued a press release announcing that it had secured FDA approval for its breast cancer therapy Revtorpyk (gedatolisib) and \"anticipates commercial launch in late Q3 2026\", representing a delayed launch timeline relative to analyst expectations. Commenting on the announcement, a Stifel analyst noted that \"late 3Q26 launch guidance seems somewhat extended.\" A Leerink analyst agreed, noting that while the \"approval was largely expected . . . we did not anticipate [a Q3 launch date] given prior commentary on launch readiness.\"<\/p>

\nCelcuity\u2019s Stock Drops Over 17%<\/span><\/b><\/p>

\nFollowing the news of Celcuity Inc.\u2019s delayed drug launch, the company\u2019s stock price fell over 17%.<\/p>

\nInvestors who purchased Celcuity Inc. (NASDAQ: CELC) securities and experienced losses may have legal rights under the federal securities laws.<\/p>

\nCONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:<\/span><\/b><\/p>

\nIf you purchased or acquired Celcuity Inc. securities and have lost money on your investment, please provide your information here: https:\/\/www.ktmc.com\/celc-celcuity-inc-investigation?utm_campaign=hc?utm_source=Businesswire&utm_medium=pressrelease&utm_campaign=celc&mktm=PR<\/a><\/p>

\nThere is no cost or obligation to speak with an attorney.<\/p>

\nABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):<\/span><\/b><\/p>

\nKessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm<\/a> in Securities and Class Actions, Legal 500\u2019s Tier 1 Rankings for Securities and M&A Litigation<\/a>, The National Law Journal\u2019s Plaintiff\u2019s Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group\u2019s Honor Roll of Most Feared Law Firms, The Legal Intelligencer\u2019s Class Action Firm of the Year<\/a>, Lawdragon\u2019s Leading Plaintiff Financial Lawyers, and Law360\u2019s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.<\/p>

\nMay be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.<\/p> Contacts<\/b>

\nJonathan Naji, Esq.\n280 King of Prussia Road\nRadnor, PA 19087\n(484) 270-1453\ninfo@ktmc.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

RADNOR, Pa.–(BUSINESS WIRE)–#classaction–Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Celcuity Inc. (NASDAQ: CE…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-46997","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/46997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46997"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/46997\/revisions"}],"predecessor-version":[{"id":47000,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/46997\/revisions\/47000"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}